Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
AstraZeneca
Mallinckrodt
McKinsey
Colorcon
Julphar
Dow
Baxter

Generated: April 21, 2018

DrugPatentWatch Database Preview

TEVETEN Drug Profile

« Back to Dashboard

Which patents cover Teveten, and when can generic versions of Teveten launch?

Teveten is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.
Drug patent expirations by year for TEVETEN
Synonyms for TEVETEN
(|AE)-|A-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Monomethanesulfonate
(E)-|A-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Methanesulfonate
(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate
(E)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thienylimidazole-5-acrylic acid monomethanesulfonate
(E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid compound with methanesulfonic acid (1:1)
(E)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-2-thiophenepropanoic acid monomethanesulfonate
143E964
144143-96-4
2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonate
4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate
4-[[2-Butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-imidazol-1-yl]methyl]benzoic acid mesylate
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]-1-imidazolyl]methyl]benzoic acid; methanesulfonic acid
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid
4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid
4-[[2-butyl-5-[(E)-3-oxidanyl-3-oxidanylidene-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid
8N2L1NX8S3
92605-EP2295430A2
92605-EP2295431A2
92605-EP2305670A1
A808180
AB0069224
AC1NR04M
AK110450
AKOS015994738
AM84399
AOB5517
C23H24N2O4S.CH4O3S
CAS-144143-96-4
CCG-222112
CHEBI:48409
CHEMBL1200987
CS-2291
D02082
DJSLTDBPKHORNY-XMMWENQYSA-N
DSSTox_CID_24217
DSSTox_GSID_44217
DSSTox_RID_80124
DTXSID7044217
E1161
Epro-sartan mesylate dihydrate
Eprosartan (mesylate)
Eprosartan mesilate
EPROSARTAN MESYLATE
Eprosartan mesylate (USAN)
Eprosartan mesylate [USAN:BAN]
Eprosartan mesylate dihydrate
Eprosartan mesylate, >=98% (HPLC)
Eprosartan mesylate, United States Pharmacopeia (USP) Reference Standard
Eprosartan mesylate|SK&F 108566|(?E)-?-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid methanesulfonate
eprosartan methanesulfonate
Eprosartan Monomethanesulfonate
Futuran
HE070981
HMS3262B17
HY-15834A
J-007923
KS-1233
LS-173203
MFCD08141807
MP-0196
Navixen
NCGC00164557-01
NCGC00167505-02
NCGC00261493-01
Regulaten
s4102
SCHEMBL41396
SK&F 108566-J
SK&F-108566-J
SK&F-108566J
SKF 108566
SKF-108566J
SR-05000001450
SR-05000001450-2
ST2412854
sunitinib and its intermediate
Teveten (TN)
Teveten SB
Tevetenz
Tox21_112186
Tox21_112186_1
Tox21_500808
UNII-8N2L1NX8S3

US Patents and Regulatory Information for TEVETEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for TEVETEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVETEN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
Queensland Health
Healthtrust
Fish and Richardson
Chubb
Farmers Insurance
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.